MEREO BIOPHARMA GROUP PLC (MREO) Debt Components
- 2025-12-31: Convertible Notes Payable, CurrentUSD $0.00; BorrowingsGBP (m); Borrowings Interest Ratepure (m).
- 2025-09-30: Convertible Notes Payable, CurrentUSD $0.00; BorrowingsGBP (m); Borrowings Interest Ratepure (m).
- 2025-06-30: Convertible Notes Payable, CurrentUSD $0.00; BorrowingsGBP (m); Borrowings Interest Ratepure (m).
- 2025-03-31: Convertible Notes Payable, CurrentUSD $0.00; BorrowingsGBP (m); Borrowings Interest Ratepure (m).
MEREO BIOPHARMA GROUP PLC Debt Components
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Convertible Notes Payable, Current USD | Borrowings GBP | Borrowings Interest Rate pure |
|---|---|---|---|
| 2025-12-31 | $0.00 | (m) | (m) |
| 2025-09-30 | $0.00 | (m) | (m) |
| 2025-06-30 | $0.00 | (m) | (m) |
| 2025-03-31 | $0.00 | (m) | (m) |
| 2024-12-31 | $5.54M | (m) | (m) |
| 2024-09-30 | $5.55M | (m) | (m) |
| 2024-06-30 | $4.93M | (m) | (m) |
| 2024-03-31 | $4.63M | (m) | (m) |
| 2023-12-31 | $0.00 | (m) | (m) |
| 2023-06-30 | (m) | 7.85M | (m) |
| 2022-12-31 | $13.33M | (m) | (m) |
| 2022-12-31 | (m) | 11.09M | (m) |
| 2022-12-31 | (m) | (m) | 6.00% |
| 2022-06-30 | (m) | 15.95M | (m) |
| 2021-12-31 | (m) | 14.38M | (m) |
| 2021-12-31 | (m) | (m) | 6.00% |
| 2020-12-31 | (m) | 16.14M | (m) |
| 2020-12-31 | (m) | (m) | 6.00% |
| 2020-06-30 | (m) | 27.76M | 6.00% |
| 2019-12-31 | (m) | 20.51M | (m) |
| 2019-06-30 | (m) | 19.73M | (m) |
| 2018-12-31 | (m) | 21.48M | (m) |
| 2017-12-31 | (m) | 20.75M | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |